GoCART

GoCART Therapeutics is a pre-clinical stage biotechnology company developing next-generation "AND"-gated CAR-T cell therapies designed to overcome the limitations of current adoptive immunotherapies. The company's proprietary platform utilizes logic-gating technology to ensure that CAR-T cells activate only upon the simultaneous detection of two distinct antigens on a single cancer cell, thereby minimizing off-target toxicity and enabling the use of high-affinity binders against previously "undruggable" targets. Their lead programs are focused on hematologic malignancies, specifically Multiple Myeloma and Acute Myeloid Leukemia, targeting combinations of CD33, CD38, and CD56. GoCART operates as a platform-centric organization, aiming to provide a modular "operating system" for cell therapy where binders can be easily swapped for different indications. The company is also a pioneer in the Decentralized Science (DeSci) movement, leveraging community-driven funding and governance through the BioDAO ecosystem.